Capstone Investment Advisors
RXRX icon

Capstone Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Capstone Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
+46,481
New +$180K ﹤0.01% 1539
2025
Q3 		– Sell
-40,303
Closed -$204K – 2043
2025
Q2 		$204K Buy
+40,303
New +$198K ﹤0.01% 1527
2024
Q2 		– Sell
-16,100
Closed -$161K – 2412
2024
Q1 		$161K Buy
+16,100
New +$179K ﹤0.01% 2059

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capstone Investment Advisors's RXRX Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 46,481 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #1539 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in RXRX as recently as Q2 2025.

Capstone Investment Advisors first reported a position in RXRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $204K in Q2 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Capstone Investment Advisors held 46,481 shares of Recursion Pharmaceuticals worth $143K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Capstone Investment Advisors position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1539 holding.
  • Capstone Investment Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Recursion Pharmaceuticals position peaked at $204K in Q2 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.